{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:08:57Z","timestamp":1787616537806,"version":"build-2736575974"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0179595","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T17:40:09Z","timestamp":1498844409000},"page":"e0179595","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience"],"prefix":"10.1371","volume":"12","author":[{"given":"Marta","family":"Garc\u00eda-Recio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cladera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ruiz de Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":true,"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hon.881","article-title":"Central nervous system dissemination in immunocompetent patients with aggressive lymphomas:incidence, risk factors and therapeutic options","volume":"27","author":"A Ferreri","year":"2009","journal-title":"Hematol Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","article-title":"CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?","volume":"26","author":"T Siegal","year":"2012","journal-title":"Blood Rev. Elsevier Ltd"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-07-101402","article-title":"Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: An International Primary CNS Lymphoma Collaborative Group report","volume":"111","author":"ND Doolittle","year":"2008","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"CY Cheah","year":"2014","journal-title":"Br J Cancer"},{"key":"ref5","first-page":"1","article-title":"Central Nervous System Disease in Hematological Malignancies: Historical Perspective and Practical Applications","volume":"36","author":"Ch-H Pui","year":"2009","journal-title":"Semin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"V Boehme","year":"2009","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bjh.12509","article-title":"Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology","volume":"163","author":"A Mcmillan","year":"2013","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates","volume":"48","author":"WM Hryniuk","year":"1969","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"BD Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref10","first-page":"829","article-title":"Common terminology criteria for adverse events (CTCAE) [Internet]","author":"GT Jun","year":"2009"},{"issue":"No. 282","key":"ref11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"Vol. 53","author":"E.L Kaplan","year":"1958","journal-title":"Journal of the American Statistical Association"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"R Peto","year":"1977","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: A single centre experience and review of the literature","volume":"159","author":"HR Guirguis","year":"2012","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1355617715000788","article-title":"Executive Dysfunction 25 Years after Treatment with Cranial Radiotherapy for Pediatric Lymphoid Malignancies","volume":"21","author":"I Schuitema","year":"2015","journal-title":"J Int Neuropsychol Soc"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-015-1994-8","article-title":"High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma","volume":"126","author":"MC Chamberlain","year":"2016","journal-title":"J Neurooncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/10428190802220527","article-title":"Intrathecal liposomal cytarabine: more friend than foe?","volume":"49","author":"D Bhojmani","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u201cunclassifiable\u201d highly aggressive B-cell lymphoma","volume":"156","author":"G Corazzelli","year":"2012","journal-title":"Br J Haematol"},{"key":"ref18","first-page":"187","article-title":"Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas","volume":"70","author":"B Kumiega","year":"2013","journal-title":"Przegl Lek"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-015-0520-3","article-title":"Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers","volume":"32","author":"W Jurczak","year":"2015","journal-title":"Med Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00277-016-2648-4","article-title":"Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial","volume":"95","author":"E Gonz\u00e1lez-Barca","year":"2016","journal-title":"Ann Hematol. Annals of Hematology"},{"key":"ref21","first-page":"786","article-title":"Phase II randomized trial of radiation-free central nervous system (CNS) prophylaxis comparing intrathecal triple therapy with liposomal cytarabine (depocyte) in adult acute lymphoblastic leukemia (all)","volume":"100","author":"R Bassan","year":"2015","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database","volume":"118","author":"A Kumar","year":"2012","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"JS Abramson","year":"2010","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.20452\/pamw.1968","article-title":"Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas","volume":"123","author":"K Krawczyk","year":"2013","journal-title":"Pol Arch Med Wewn"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000380913","article-title":"Safety and efficacy of liposomal cytarabine in the treatment of neoplastic meningitis","volume":"89","author":"F Jahn","year":"2015","journal-title":"Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0179595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T19:36:13Z","timestamp":1750448173000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0179595"}},"subtitle":[],"editor":[{"given":"Fernando","family":"de Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0179595","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}